Skip to main navigation

Careers
Contact

Menu

Skip to content

Company
Investors
Pipeline
Platforms
- Immuno-Oncology Assets
  - G-MABs™
  - CAR-T
  - ADCs
  - iTAbs
  - Oncolytic Virus
- Pain Management Assets
  - ZTlido™
  - RTX
Translational Efficiencies

News Releases

fundamentals sub menu

Fundamentals

Year

Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations

Apr 16, 2019

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

Apr 15, 2019

Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

Apr 10, 2019

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

Mar 26, 2019

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Mar 22, 2019

CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

Mar 11, 2019

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

Mar 11, 2019

Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

Feb 25, 2019

Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

Feb 12, 2019

Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019

Jan 22, 2019

Pagination

Current page 1
Page 2
Next page
Last page

Tools

Print Page
Email Alerts
RSS Feeds
Email Page

Clinical Trials
clinicaltrials@sorrentotherapeutics.com

Investors
investors@sorrentotherapeutics.com

Business Development
business@sorrentotherapeutics.com

Media Requests
mediarelations@sorrentotherapeutics.com

© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.

Terms of Use
Privacy Policy
DMCA
Trademarks
Linking Policy

LinkedIn

MENU

Company
Investors
Pipeline
Platforms
- Immuno-Oncology Assets
- Pain Management Assets
  - RTX
  - ZTlido™
Translational Efficiencies
Careers
Contact